Article
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2015
Chen J S, Hsu C, Chiang N J, Tsai C S, Tsou H H, Huang S F, Bai L Y, Chang I C, Shiah H S, Ho C L, Yen C J, Lee K D, Chiu C F, Rau K M, Yu M S, Yang Y, Hsieh R K, Chang J Y, Shan Y S, Chao Y, Chen L T
Abstract excerpt
BACKGROUND: Previous clinical trials have not proved that adding epidermal growth factor receptor inhibitors to chemotherapy confers a survival benefit for patients with advanced biliary tract cancer (ABTC). Whether the KRAS mutation status of tumor cells confounded the results of past studies is unknown. PATIENTS AND METHODS: ABTC patients stratified by KRAS status, Eastern Cooperative Oncology Group performance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.